Literature DB >> 17786098

Atopic dermatitis and Valpha24+ natural killer T cells.

Fulya Ilhan1, Basak Kandi, Handan Akbulut, Dilara Turgut, Demet Cicek.   

Abstract

OBJECTIVE: Atopic dermatitis is a chronic inflammatory skin disease associated with cutaneous hyperreactivity to environmental triggers and is often the first step in the atopic march that results in asthma and allergic rhinitis. Helper T cells and their cytokines, in addition to IgE and eosinophils, play a major role in the pathogenesis of atopic dermatitis. Natural killer T (NKT) cells may play a role in atopic dermatitis status.
METHODS: The authors examined the percentage of Valpha24+CD161+ NKT cells and CD3+CD16+ CD56+ NKT cells in peripheral blood from 23 patients with atopic dermatitis aged 8 to 35 years (mean, 21.77+/-2.88 years) and 30 healthy controls aged 18 to 32 years (mean, 24.32+/-2.44 years) by using flow cytometric analysis. The mean percentages of Valpha24+CD161+ NKT cell subtypes in the atopic dermatitis group and the healthy group were 0.29%+/-0.02% and 0.42%+/-0.05%, respectively (P<.001).
RESULTS: Percentages of Valpha24+CD161+ NKT cell subtypes are significantly lower in patients with atopic dermatitis than healthy individuals. On the other hand, the CD3+CD16+CD56+ NKT cell subtype does not differ between the groups.
CONCLUSIONS: The reduction of Valpha24+CD161+ NKT cells subtypes may be involved in the immunopathogenesis of atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786098     DOI: 10.1111/j.1540-9740.2007.06458.x

Source DB:  PubMed          Journal:  Skinmed        ISSN: 1540-9740


  2 in total

1.  Altered peripheral invariant natural killer T cells in atopic dermatitis.

Authors:  Edit Gyimesi; Georgina Nagy; Éva Remenyik; Sándor Sipka; Margit Zeher; Tamás Bíró; Andrea Szegedi
Journal:  J Clin Immunol       Date:  2011-06-21       Impact factor: 8.317

Review 2.  Roles and therapeutic potential of CD1d-Restricted NKT cells in inflammatory skin diseases.

Authors:  Sung Won Lee; Hyun Jung Park; Luc Van Kaer; Seokmann Hong
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.